M. Özen

Clinical outcomes of cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors in patients with male breast cancer: A multicenter study

Ö. Acar, A. Erdoğan, S. Kılıçkap, 2022, Breast.

Prognostic factors of perioperative FLOT regimen in operable gastric and gastroesophageal junction tumors: real-life data (Turkish Oncology Group)

M. Dogan, E. Çavdar, Feyza Firat, 2022, Turkish journal of medical sciences.

First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer

T. Kaçan, M. Karaağaç, S. Kılıçkap, 2022, Bosnian journal of basic medical sciences.

Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer

A. Arıcan, D. Aydın, M. Eryılmaz, 2024, BMC cancer.

The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study.

A. Erdoğan, S. Kılıçkap, B. Çakar, 2024, International journal of clinical oncology.